nt-814
Small moleculeexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2016 (NCT02692157)
Timeline
Indications
Mechanism of action
- Neurokinin 3 receptorANTAGONIST
TACR3 antagonist
- Neurokinin 1 receptorANTAGONIST
TACR1 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nt-814
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04903821 | Phase 1 | Jun 1, 2021 | Bayer |
| NCT04654897 | Phase 1 | Sep 30, 2020 | NeRRe Therapeutics Ltd., Quotient |
| NCT03596762 | Phase 2 | Oct 31, 2018 | NeRRe Therapeutics Ltd. |
| NCT02865538 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | NeRRe Therapeutics Ltd. |
| NCT02692157 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2016 | Columbia University, National Institute on Drug Abuse (NIDA) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeRRe Therapeutics Ltd. | For profit | 3 | 3 | 2 | 2016 |
| Bayer | For profit | 1 | 1 | 1 | 2021 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2016 |
| Quotient | For profit | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1